[8] Lebrikizumab was approved for medical use in the European Union in November 2023,[8] in Canada in June 2024,[5] and in the United States in September 2024.

[10][11][12][13] Lebrikizumab is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents twelve years and older with a body weight of at least 40 kilograms (88 lb) who are candidates for systemic therapy.

IL-13 is thought to induce the expression of another signalling protein, periostin, by epithelial cells of the bronchi.

[14][15] This theory is supported by the fact that people with high periostin levels responded significantly better to lebrikizumab in the phase II study: the forced expiratory volume in 1 second (FEV1) was 8.2% higher than under placebo in this group (measured from the respective baselines), while low-periostin patients had 1.6% higher FEV1, and the average value for all patients was 5.5%.

[8] Lebrikizumab is under investigation as an immunosuppressive medication for the treatment of asthma that cannot be adequately controlled with inhalable glucocorticoids.